Digitoxin, at concentrations commonly found in the plasma of cardiac patients, antagonizes etoposide and idarubicin activity in K562 leukemia cells

Leukemia Research

Volumn 30, Issue 7, 2006, Pages 895-898

  López Lázaro, Miguel ^a,b   Pastor, Nuria ^a   Azrak, Sami S ^b   Ayuso, Maria Jesús ^a   Cortés, Felipe ^a   Austin, Caroline A ^b  

^a UNIVERSITY OF SEVILLE   (Spain)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Digitoxin; Etoposide; Idarubicin; K 562; Topoisomerase II

Indexed keywords

DIGITOXIN; ETOPOSIDE; IDARUBICIN;

ARTICLE; CELL STRAIN K 562; CONTROLLED STUDY; DRUG EFFECT; HEART; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

AMSACRINE; ANTINEOPLASTIC AGENTS; DIGITOXIN; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ETOPOSIDE; HUMANS; IDARUBICIN; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC; MITOXANTRONE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33744540990     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.11.005     Document Type: Article

References (10)

1. Repke K. Biomembranes, basic and medical research (1988), Springer Verlag, Berlin
2. Fortune J.M., and Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucl Acid Res Mol Biol 64 (2000) 221-253
3. Strick R., Strissel P.L., Gavrilov K., and Levi-Setti R. Cation-chromatin binding as shown by ion microscopy is essential for the structural integrity of chromosomes. J Cell Biol 155 6 (2001) 899-910
4. Willmore E., Frank A.J., Padget K., Tilby M.J., and Austin C.A. Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique. Mol Pharmacol 54 1 (1998) 78-85
5. Haux J., Klepp O., Spigset O., and Tretli S. Digitoxin medication and cancer; case control and internal dose-response studies. BMC Cancer 1 (2001) 11
6. Lopez-Lazaro M., Pastor N., Azrak S.S., Ayuso M.J., Austin C.A., and Cortes F. Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J Nat Prod 68 11 (2005) 1642-1645
7. Errington F., Willmore E., Tilby M.J., Li L., Li G., Li W., et al. Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. Mol Pharmacol 56 6 (1999) 1309-1316
8. Jackson G.H., Taylor P.R., Iqbal A., Galloway M.J., Turner G., Haynes A., et al. The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy. Leukemia 11 8 (1997) 1193-1196
9. Belz G.G., Breithaupt-Grogler K., and Osowski U. Treatment of congestive heart failure-current status of use of digitoxin. Eur J Clin Invest 31 2 (2001) 10-17
10. Roever C., Ferrante J., Gonzalez E.C., Pal N., and Roetzheim R.G. Comparing the toxicity of digoxin and digitoxin in a geriatric population: should an old drug be rediscovered?. South Med J 93 2 (2000) 199-202